about
Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary diseaseFEV manoeuvre induced changes in breath VOC compositions: an unconventional view on lung function testsLung volume reduction surgery for diffuse emphysemaInspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension.Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.Increased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients.Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patientsThe inspiratory capacity/total lung capacity ratio as a predictor of survival in an emphysematous phenotype of chronic obstructive pulmonary diseaseThe effect of acute magnesium loading on the maximal exercise performance of stable chronic obstructive pulmonary disease patients.The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary DiseaseSpirometric correlates of dyspnea improvement among emergency department patients with chronic obstructive pulmonary disease exacerbationThe Impact of Homogeneous Versus Heterogeneous Emphysema on Dynamic Hyperinflation in Patients With Severe COPD Assessed for Lung Volume Reduction.Exercise-Induced Changes in Exhaled NO Differentiates Asthma With or Without Fixed Airway Obstruction From COPD With Dynamic Hyperinflation.Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.Phenotypes of chronic obstructive pulmonary disease.Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary diseasePulmonary characteristics in COPD and mechanisms of increased work of breathing.A review of the role of FEV1 in the COPD paradigm.Acute effects of Expiratory Positive Airway Pressure (EPAP) on different levels in ventilation and electrical activity of sternocleidomastoid and parasternal muscles in Chronic Obstructive Pulmonary Disease (COPD) patients: a randomized controlled tDefining phenotypes in COPD: an aid to personalized healthcare.Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease.Pathophysiology of dyspnea in COPD.Non-linear parameters of specific resistance loops to characterise obstructive airways diseases.Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea.Obesity in COPD: Revealed and Unrevealed Issues.A Comparison of Pain, Fatigue, Dyspnea and their Impact on Quality of Life in Pulmonary Rehabilitation Participants with Chronic Obstructive Pulmonary Disease.Toll-like receptor 2 and 4 have Opposing Roles in the Pathogenesis of Cigarette Smoke-induced Chronic Obstructive Pulmonary Disease.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.Changes in the superior vena cava area during inspiration and expiration in relation to emphysema.Endoscopic lung volume reduction coil treatment in patients with very low FEV1: an observational study.New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
P2860
Q24185964-4C5499A9-225E-458F-A649-B9ECBD2BCAFFQ27339338-EE6FA1F5-C977-4FA0-92DE-8F434723D22BQ28279120-CE590F2E-1C35-4B81-B78E-696BFF65ABC9Q33788576-F670B1A3-B13D-48F1-B652-B50A0F3C31E8Q33890852-DCA2F995-884B-41F3-9392-465B2DB63E16Q34340387-EFFDBFC8-A133-44DE-9C95-D700D6F69E8EQ35089175-E50E8B8B-9AE3-4DDA-BD57-79E71E49FD9EQ35508579-1861A7A9-28A2-4A33-9B4B-6DF8CE678364Q35862156-3C596962-2614-4129-84EB-5803315FCE26Q36017283-831D1C88-290E-437F-957C-E735CD81842DQ36075457-DA303003-4F60-48AE-B938-32E20CB40258Q36469780-9822459C-419E-4F5E-A726-09F5EC64C2C6Q36647156-4A183D99-DEB5-4EE4-A78C-544C01C632A2Q36822542-EA2224A4-BCFF-4B27-BE5D-6B0244A86C14Q36956720-FA355F8A-3C4A-405E-AD14-E3F780AA80CEQ37008634-E6B59914-BB87-4D87-80DB-2FEAE1C0CAC8Q37036951-A29FA4DD-D5D0-4518-A9BC-5D8B96AF8574Q37264613-45C903CB-EEF2-49B7-9E4E-5D37554CB802Q37313126-E98185C4-9CB7-481D-8BF2-8D327EA18FEEQ37524591-2A651764-583D-41E7-9B65-A4A29D940E3BQ38208244-49AEBF7A-512C-4B14-8594-4DC6B335028AQ38946604-19AAE88A-B28E-4385-A732-BC0F57AAADD9Q39170919-A3D85D35-28A4-4CA5-836E-10212B0B6064Q40981884-598F2059-1F47-4DB5-B720-546B60EEB0F1Q41223119-2737A58F-BC3F-4CDA-89C3-63DFB18D2BD6Q47359885-F72FBAEB-AAD6-4B7A-AFEF-7A601EC58586Q47654912-F5066A8B-DC44-47FC-A955-61C45E30A27BQ47746183-425D6271-C3D4-4A83-9E36-8CBC0DB7C827Q47966525-75C2C675-2AA7-4649-AC87-0702EB71B8D4Q51713185-7F46B2A0-A0F7-49D3-924B-769E77EDD327Q51747791-14259CAA-96C6-443C-A2EC-0EF715044C38Q58759101-5BA93CA3-9553-469D-B7FB-9664A4B2BBD5
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Why does the lung hyperinflate?
@ast
Why does the lung hyperinflate?
@en
type
label
Why does the lung hyperinflate?
@ast
Why does the lung hyperinflate?
@en
prefLabel
Why does the lung hyperinflate?
@ast
Why does the lung hyperinflate?
@en
P1476
Why does the lung hyperinflate?
@en
P2093
Gary T Ferguson
P304
P356
10.1513/PATS.200508-094DO
P577
2006-04-01T00:00:00Z